Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Keiya Uriu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Virology
Jiahao Ma et al.
Summary: Utilizing Trimer-Tag technology, scientists produced stable S-Trimer vaccine candidates for COVID-19, which showed tightly closed conformations and pH-dependent stability. This platform technology has the potential to contribute to the production of effective COVID-19 subunit vaccines.
JOURNAL OF VIROLOGY
(2021)
Article
Medicine, General & Internal
Peter Richmond et al.
Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.
Article
Multidisciplinary Sciences
Joshua G. Liang et al.
Summary: Researchers have developed a trimeric vaccine candidate S-Trimer for COVID-19 based on Trimer-Tag technology. Immunization studies in animal models showed high levels of neutralizing antibodies and cellular immune responses, and protection from SARS-CoV-2 challenge in rhesus macaques. This technology may be crucial for scalable production of subunit vaccines against emerging RNA viruses.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Mine Durusu Tanriover et al.
Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Paul T. Heath et al.
Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Fan Wu et al.
